Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement – Recommendation to Discontinue Prescribing and Dispensing

ISSUE: FDA is recommending health care professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 milligrams (mg) of acetaminophen per tablet, capsule or other dosage unit. There are no available data to show that taking more than 325 mg of acetaminophen per dosage unit provides additional benefit that outweighs the added risks for liver injury. Further, limiting the amount of acetaminophen per dosage unit will reduce the risk of severe liver injury from inadvertent acetaminophen overdose, which can lead to liver failure, liver transplant, and death.

via Safety Alerts for Human Medical Products > Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement – Recommendation to Discontinue Prescribing and Dispensing.

You like your liver?  You can keep your liver.

Smart Appliances Hacked – over 750k Malicious Emails Sent – SlashGear

A security service provider called Proofpoint has issued a report detailing what it believes to be the first documented attack on the Internet of Things. According to the report, over 750,000 malicious emails were sent out using over 100,000 compromised devices on the Internet of Things. The compromised devices include appliances, routers, TVs, and connected refrigerators.

via Smart appliances hacked to send out over 750k malicious emails – SlashGear.

Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes — NEJM

Conclusions

We observed a J-shaped association between BMI and mortality among all participants and among those who had ever smoked and a direct linear relationship among those who had never smoked. We found no evidence of lower mortality among patients with diabetes who were overweight or obese at diagnosis, as compared with their normal-weight counterparts, or of an obesity paradox.

via Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes — NEJM.

Farxiga (dapagliflozin) – Think Diabetes

The FDA has approved dapagliflozin (Farxiga) for treatment of type 2 diabetes in adults, along with diet and exercise, the agency said in a statement.

The approval comes with strings, however: drugmakers Bristol-Myers Squibb and AstraZeneca must conduct six post-market studies, which include a cardiovascular outcomes trial in patients with baseline cardiovascular disease risks, a bladder cancer risk trial, an animal study looking at drug-induced urinary flow and bladder tumor promotion, two trials on risks in pediatric patients, and an enhanced pharmacovigilance program to study liver abnormalities and pregnancy outcomes.

via FDA Approves New Diabetes Drug.

Cardiologists Should Mind Radiation Doses, ESC Says

Because radiation used in imaging tests is proven to cause cancer, they wrote, “cardiologists should make every effort to give ‘the right imaging exam, with the right dose, to the right patient.’

via Cardiologists Should Mind Radiation Doses, ESC Says.

We are seeing more applicant/patient initiated cardiac scans.  I recently became aware of a life insurance application where the underwriter requested a repeat cardiac CT scan.  The applicant’s cardiologist flatly rejected this course of action in an a asymptomatic patient with a correspondingly low CHD risk score.

Now you understand the cardiologist’s thinking.

Did I hear someone say “litigation risk”?